Novel approaches in fighting herpes simplex virus infections

Sarah S. Wilson, Esra Fakioglu, Betsy Herold

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The development of novel strategies to eradicate herpes simplex virus (HSV) is a global public health priority. While acyclovir and related nucleoside analogues provide successful modalities for treatment and suppression, HSV remains highly prevalent worldwide and is a major cofactor fueling the HIV epidemic. HSV is the predominant cause of genital ulcerative disease, and neonatal and sporadic infectious encephalitis. Asymptomatic shedding, which occurs more frequently than previously appreciated, contributes to viral transmission. Acyclovir resistance may be problematic for immunocompromised patients and highlights the need for new safe and effective agents. Ideally, vaccines to prevent infection, drugs to inhibit the establishment of or reactivation from latency, or vaginal microbicides to prevent sexual and perinatal transmission are needed to control the epidemic. This review summarizes current therapeutic options and strategies in development.

Original languageEnglish (US)
Pages (from-to)559-568
Number of pages10
JournalExpert Review of Anti-Infective Therapy
Volume7
Issue number5
DOIs
StatePublished - Jun 2009

Fingerprint

Virus Diseases
Simplexvirus
Acyclovir
Infant, Newborn, Diseases
Health Priorities
Immunocompromised Host
Anti-Infective Agents
Nucleosides
Vaccines
Public Health
HIV
Infection
Pharmaceutical Preparations
Therapeutics

Keywords

  • Acyclovir
  • Herpes simplex virus
  • Microbicide
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology

Cite this

Novel approaches in fighting herpes simplex virus infections. / Wilson, Sarah S.; Fakioglu, Esra; Herold, Betsy.

In: Expert Review of Anti-Infective Therapy, Vol. 7, No. 5, 06.2009, p. 559-568.

Research output: Contribution to journalArticle

Wilson, Sarah S. ; Fakioglu, Esra ; Herold, Betsy. / Novel approaches in fighting herpes simplex virus infections. In: Expert Review of Anti-Infective Therapy. 2009 ; Vol. 7, No. 5. pp. 559-568.
@article{fe74d0d53d74464aae47922d58b4ba56,
title = "Novel approaches in fighting herpes simplex virus infections",
abstract = "The development of novel strategies to eradicate herpes simplex virus (HSV) is a global public health priority. While acyclovir and related nucleoside analogues provide successful modalities for treatment and suppression, HSV remains highly prevalent worldwide and is a major cofactor fueling the HIV epidemic. HSV is the predominant cause of genital ulcerative disease, and neonatal and sporadic infectious encephalitis. Asymptomatic shedding, which occurs more frequently than previously appreciated, contributes to viral transmission. Acyclovir resistance may be problematic for immunocompromised patients and highlights the need for new safe and effective agents. Ideally, vaccines to prevent infection, drugs to inhibit the establishment of or reactivation from latency, or vaginal microbicides to prevent sexual and perinatal transmission are needed to control the epidemic. This review summarizes current therapeutic options and strategies in development.",
keywords = "Acyclovir, Herpes simplex virus, Microbicide, Vaccine",
author = "Wilson, {Sarah S.} and Esra Fakioglu and Betsy Herold",
year = "2009",
month = "6",
doi = "10.1586/ERI.09.34",
language = "English (US)",
volume = "7",
pages = "559--568",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Novel approaches in fighting herpes simplex virus infections

AU - Wilson, Sarah S.

AU - Fakioglu, Esra

AU - Herold, Betsy

PY - 2009/6

Y1 - 2009/6

N2 - The development of novel strategies to eradicate herpes simplex virus (HSV) is a global public health priority. While acyclovir and related nucleoside analogues provide successful modalities for treatment and suppression, HSV remains highly prevalent worldwide and is a major cofactor fueling the HIV epidemic. HSV is the predominant cause of genital ulcerative disease, and neonatal and sporadic infectious encephalitis. Asymptomatic shedding, which occurs more frequently than previously appreciated, contributes to viral transmission. Acyclovir resistance may be problematic for immunocompromised patients and highlights the need for new safe and effective agents. Ideally, vaccines to prevent infection, drugs to inhibit the establishment of or reactivation from latency, or vaginal microbicides to prevent sexual and perinatal transmission are needed to control the epidemic. This review summarizes current therapeutic options and strategies in development.

AB - The development of novel strategies to eradicate herpes simplex virus (HSV) is a global public health priority. While acyclovir and related nucleoside analogues provide successful modalities for treatment and suppression, HSV remains highly prevalent worldwide and is a major cofactor fueling the HIV epidemic. HSV is the predominant cause of genital ulcerative disease, and neonatal and sporadic infectious encephalitis. Asymptomatic shedding, which occurs more frequently than previously appreciated, contributes to viral transmission. Acyclovir resistance may be problematic for immunocompromised patients and highlights the need for new safe and effective agents. Ideally, vaccines to prevent infection, drugs to inhibit the establishment of or reactivation from latency, or vaginal microbicides to prevent sexual and perinatal transmission are needed to control the epidemic. This review summarizes current therapeutic options and strategies in development.

KW - Acyclovir

KW - Herpes simplex virus

KW - Microbicide

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=68249137329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249137329&partnerID=8YFLogxK

U2 - 10.1586/ERI.09.34

DO - 10.1586/ERI.09.34

M3 - Article

VL - 7

SP - 559

EP - 568

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 5

ER -